If you’re looking for a comprehensive guide to ICD-10 anemia of CKD — including the exact codes, when to diagnose it, and how to manage it — here’s the short version: anemia of chronic kidney disease is coded as D63.1 in ICD-10-CM, and it must be coded in conjunction with the underlying CKD code (N18.1–N18.6). This dual-coding requirement trips up coders and clinicians constantly. Anemia affects roughly 37% of CKD patients overall, but that number climbs to over 50% in stage 4 and nearly 75% in stage 5.
This isn’t just a billing detail. Proper ICD-10 coding directly impacts treatment authorization, EPO reimbursement, and quality metrics. Below, we’ll walk through the specific codes, diagnostic thresholds, lab workup, and current treatment guidelines so you can manage this condition accurately from documentation to bedside.
ICD-10 Codes for Anemia of CKD: Getting It Right
The primary code is D63.1 — Anemia in chronic kidney disease. This falls under the “Anemia in chronic diseases classified elsewhere” category, which means it cannot stand alone. You must code the underlying CKD first.
| Condition | ICD-10-CM Code | Sequencing |
|---|---|---|
| CKD Stage 1 | N18.1 | Code first |
| CKD Stage 2 (mild) | N18.2 | Code first |
| CKD Stage 3a | N18.31 | Code first |
| CKD Stage 3b | N18.32 | Code first |
| CKD Stage 4 (severe) | N18.4 | Code first |
| CKD Stage 5 | N18.5 | Code first |
| ESRD | N18.6 | Code first |
| Anemia of CKD | D63.1 | Code second |
| Iron deficiency (if present) | D50.x | Additional code |
Common coding mistake: Using D64.9 (anemia, unspecified) instead of D63.1 when CKD is documented. This loses specificity, can trigger claim denials, and underrepresents the true prevalence of CKD-associated anemia in institutional data.
If the patient also has iron deficiency anemia contributing to their CKD anemia — which occurs in roughly 40–60% of cases — you should add the appropriate D50.x code. Documentation must clearly link the anemia to the kidney disease for D63.1 to be assigned.
Why CKD Causes Anemia: The Mechanism in 60 Seconds
Healthy kidneys produce about 90% of the body’s erythropoietin (EPO), the hormone that tells bone marrow to make red blood cells. As nephrons are destroyed in CKD, EPO production drops. By the time GFR falls below 30 mL/min (stage 4), most patients can’t maintain adequate hemoglobin levels.
But EPO deficiency isn’t the whole story. CKD anemia is multifactorial:
- Functional iron deficiency — Hepcidin levels rise due to chronic inflammation, trapping iron in storage sites and blocking gut absorption
- Shortened red blood cell lifespan — Uremic toxins damage RBC membranes, reducing survival from 120 days to roughly 60–90 days
- Chronic inflammation — Elevated IL-6 and CRP suppress erythropoiesis directly
- Blood loss — Hemodialysis circuits, frequent phlebotomy, and uremic platelet dysfunction all contribute
- Nutritional deficiencies — Folate and B12 depletion from dietary restrictions and dialysis losses
Diagnostic Criteria and Lab Workup
KDIGO guidelines recommend screening for anemia when hemoglobin drops below 13 g/dL in men or 12 g/dL in women. However, the formal diagnosis of anemia in CKD is typically made at:
- Hb < 13.0 g/dL in adult males
- Hb < 12.0 g/dL in adult females
Screening should begin at CKD stage 3 (GFR < 60), even if the patient is asymptomatic. Here’s the recommended initial workup:
| Test | Purpose | Key Threshold |
|---|---|---|
| Complete blood count (CBC) | Confirm anemia, assess MCV | Hb below sex-specific cutoff |
| Reticulocyte count | Assess marrow response | Low/inappropriately normal in CKD |
| Serum ferritin | Iron stores | < 100 ng/mL (non-dialysis); < 200 ng/mL (dialysis) |
| Transferrin saturation (TSAT) | Iron availability | < 20% suggests iron deficiency |
| Serum iron & TIBC | Iron metabolism | Low iron with high TIBC = true deficiency |
| Vitamin B12 & folate | Rule out nutritional causes | B12 < 200 pg/mL; folate < 4 ng/mL |
| CRP / hepcidin (if available) | Assess inflammatory component | Elevated CRP suggests functional iron deficiency |
Pro tip for clinicians: A ferritin between 100 and 500 ng/mL with a TSAT under 20% strongly suggests functional iron deficiency — the patient has iron in storage but can’t mobilize it. This distinction changes treatment significantly.
Treatment: Current Guidelines
Step 1: Correct Iron Deficiency First
Before reaching for an ESA, iron status must be optimized. KDIGO recommends a trial of IV iron if ferritin is < 500 ng/mL and TSAT is < 30%. In practice, most nephrologists prefer IV iron (ferric carboxymaltose, iron sucrose) over oral formulations because uremic patients absorb oral iron poorly due to elevated hepcidin.
Step 2: Erythropoiesis-Stimulating Agents (ESAs)
If hemoglobin remains below 10 g/dL despite adequate iron stores, ESAs such as epoetin alfa or darbepoetin alfa are initiated. The target hemoglobin is 10–11.5 g/dL — not normal. The TREAT and CHOIR trials showed that targeting Hb above 13 g/dL with ESAs increased stroke and cardiovascular events.
Step 3: HIF-PHI — The Newer Option
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) like roxadustat, daprodustat, and vadadustat represent a newer oral approach. They stimulate endogenous EPO production and improve iron mobilization simultaneously. Daprodustat (Jesduvroq) was FDA-approved in 2023 for CKD anemia in adults on dialysis. These drugs are particularly useful for patients with ESA hyporesponsiveness or injection fatigue.
Anemia Prevalence by CKD Stage
| CKD Stage | GFR (mL/min) | Anemia Prevalence | Screening Frequency |
|---|---|---|---|
| Stage 1–2 | ≥ 60 | ~8–10% | As clinically indicated |
| Stage 3a–3b | 30–59 | ~20–25% | At least annually |
| Stage 4 | 15–29 | ~50–55% | Every 6 months |
| Stage 5 / Dialysis | < 15 | ~70–75% | Every 3 months (monthly on ESAs) |
When to See a Doctor
If you have known CKD and experience any of the following, request a hemoglobin check promptly:
- New or worsening fatigue that interferes with daily activities
- Shortness of breath with routine exertion (climbing stairs, walking to the mailbox)
- Persistent pallor, dizziness, or cold intolerance
- Heart palpitations or new chest discomfort
- Hemoglobin hasn’t been checked in over 6 months (stage 3+)
Untreated CKD anemia accelerates left ventricular hypertrophy and independently increases mortality risk. Early detection and treatment genuinely change outcomes.
Frequently Asked Questions
What is the exact ICD-10 code for anemia of chronic kidney disease?
The code is D63.1 (Anemia in chronic kidney disease). It must always be sequenced after the underlying CKD code (N18.1–N18.6). Using D63.1 alone without a CKD code will result in a coding error.
At what hemoglobin level should ESAs be started in CKD patients?
Most guidelines recommend initiating ESAs when hemoglobin falls below 10 g/dL, iron deficiency has been corrected (ferritin > 100, TSAT > 20%), and the patient is symptomatic. The target is 10–11.5 g/dL — overshooting to normal hemoglobin levels increases cardiovascular risk.
Can anemia of CKD be reversed?
It can be effectively managed but rarely fully reversed unless kidney function is restored (e.g., successful transplant). Post-transplant patients often see hemoglobin normalize within 3–6 months as the new kidney produces adequate EPO. In all other CKD patients, ongoing treatment is required.
Why is IV iron preferred over oral iron in CKD?
CKD causes elevated hepcidin levels, which block iron absorption in the gut. Oral iron supplements are therefore poorly absorbed and frequently cause GI side effects without meaningfully raising iron stores. IV iron bypasses this entirely, delivering iron directly to transferrin and storage sites. Studies show IV iron raises hemoglobin 1–2 g/dL more effectively than oral iron in CKD populations.
Does anemia of CKD affect dialysis patients differently?
Yes. Dialysis patients face additional blood loss from the dialysis circuit itself (estimated 1–3 grams of iron lost per year on hemodialysis), more frequent phlebotomy, and greater inflammatory burden. They require more aggressive iron replacement and closer hemoglobin monitoring — typically monthly when on ESA therapy.
